Skip to Content

'
Issa F. Khouri, M.D.

Present Title & Affiliation

Primary Appointment

Professor Medicine & Internist, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Bone Marrow Center Medical Director, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: Box 423
Houston, TX 77030-4095
Phone: (713) 792-8750
Fax: (713) 794-4902

Education & Training

Degree-Granting Education

1983 University of Rome, "La Sapienza", Rome, Italy, MD, Internal Medicine

Postgraduate Training

1989-1993 Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
1988-1989 Chief Resident Internal Medicine Residency, North Eastern Ohio University College of Medicine, Rootstown, OH
1987-1989 Internal Medicine Residency, North Eastern Ohio University College of Medicine, Rootstown, OH
1986-1987 Transitional Residency, North Eastern Ohio University of College of Medicine, Rootstown, OH
1985-1986 Graduate, Medical Sciences, Medical College of Ohio at Toledo, Toledo, OH

Honors and Awards

2007 M. D. Anderson/Division of Medicine Nominee for Clinical research Award
2006 M. D. Anderson/Division of Medicine Nominee for Clinical research Award
2003 The Berlex Oncology Award in Patient-Oriented Research. Advisor to the first Place winner of the Seventh Annual Trainee Recognition Day at The M. D. Anderson Cancer Center
1993 M. D. Anderson Annual Clinical Training Research Project Competition
1991-1992 M. D. Anderson Research Funds Competition Recipient

Selected Publications

Peer-Reviewed Original Research Articles

1. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. Am J Hematol 88(3):198-200, 3/2013. e-Pub 1/24/2013. PMID: 23345254.
2. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 3/2013. e-Pub 11/2/2012. PMID: 23128322.
3. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 3/2013. e-Pub 1/18/2013. PMID: 23330820.
4. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-26, 12/2012. e-Pub 6/29/2012. PMID: 22750645.
5. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 6/28/2012. e-Pub 5/14/2012. PMID: 22586182.
6. Khouri IF, Bassett R, Poindexter N, O'Brien S, Bueso-Ramos CE, Hsu Y, Ferrajoli A, Keating MJ, Champlin R, Fernandez-Vina M. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-Term Follow-Up, Prognostic Factors, and Effect of Human Leukocyte Histocompatibility Antigen Subtype on Outcome. Cancer. e-Pub 3/31/2011. PMID: 21455998.
7. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 3/2011. e-Pub 7/30/2010. PMID: 20674757.
8. Kr÷ger N, Bacher U, Bader P, B÷ttcher S, Borowitz MJ, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse Following Allogeneic Stem Cell Transplantation. Part II: Chronic Leukemias, Myeloproliferative Neoplasms, and Lymphoid Malignancies. Biol Blood Marrow Transplant 16(10):1325-46, 10/2010. e-Pub 7/15/2010. PMID: 20637879.
9. Kr÷ger N, Bacher U, Bader P, B÷ttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Macapintac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes. Biol Blood Marrow Transplant 16(9):1187-211, 9/2010. e-Pub 6/14/2010. PMID: 20558311.
10. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15(12):1555-62, 12/2009. e-Pub 9/25/2009. PMID: 19896079.
11. Cheng YC, Rondˇn G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol 90(5):627-34, 12/2009. e-Pub 12/9/2009. PMID: 19998065.
12. Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A, Van Besien K, Dipersio J. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 50(9):1412-21, 9/2009. PMID: 19603345.
13. Lazarus HM, Carreras J, Boudreau C, Loberiza FR, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, Serna DS, Horowitz MM, Rizzo JD, Center For International Blood & Marrow Transplant Research (CIBMTR). Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 14(12):1323-33, 12/2008. PMCID: PMC2638759.
14. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 9/2008. e-Pub 6/17/2008. PMID: 18564354.
15. Rondˇn G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14(8):859-66, 8/2008. PMID: 18640568.

Abstracts

1. Ciurea SO, Aung F, de Lima M, Thall PF, Rondon G, Kebriaei P, Alousi A, Shpall EJ, Hosing C, Khouri IF, Champlin RE, Fernandez-Vina M. Anti-HLA antibodies and Graft Rejection in Hematopoietic Stem Cell Transplantation. Blood 116(21):229 (#519), 11/2010.
2. Khouri IF, Bassett R, Cano P, O'Brien S, Hsu Y, Bueso-Ramos CE, Harrell R, Okoroji GJ, de Padua Silva L, Ferrajoli A, Champlin R, McMannis J, Fernandez-Vina M. Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). Blood 116(21):1055 (#2548), 11/2010.
3. Okoroji GJ, de Padua Silva L, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri IF. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood 116(21):1442 (#3510), 11/2010.
4. Alousi AM, Andersson BS, Saliba RM, Botnick W, Rondon G, Shpall EJ, deLima M, Popat U, Hosing C, Kebriaei P, Khouri I, Qazilbash M, Anderlini P, Nieto Y, Ciurea S, Jones R, Champlin R. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood 116(21):967 (#2341), 11/2010.

Last updated: 8/15/2013